

Curriculum Vitae

LUTZ NAEHRLICH PD Dr. med.
d.o.b. April, 18th 1966, in Frankfurt/Main, Germany

University Education

2016 Habilitation Pediatric, JLU
1994 Doctorate Medicine, Friedrich-Alexander-University Erlangen
1987-1993 Studies of Medicine, Friedrich-Alexander-University Erlangen

Scientific Career

2020- Pharmacovigilance study manager des European Cystic Fibrosis Society Patient Registry
2017-2020 Medical Director of the European Cystic Fibrosis Society Patient Registry
2014- Medical Director of the German Cystic Fibrosis Registry
2013- PI at UGMLC
2012-2018 Lead of the AG Cystic Fibrosis, Gesellschaft für Pädiatrische Pneumologie
2010- Consultant at the Department of Pediatrics, JLU
2001-2010 Consultant at the Department of Pediatrics, Friedrich-Alexander-University Erlangen
1993-2001 Fellow at the Department of Pediatrics, Friedrich-Alexander-University Erlangen

Awards and Honors

2004 Poster-Award - Gesellschaft für Pädiatrische Pneumologie

Citation Record

Total citations: 2707; h-index:25; h-index since 2017: 23 (Google Scholar Oct, 8th 2022)

Top-10 selected Publications

Sorg AL, Bergfeld L, Jank M, Corman V, Semmler I, Goertz A, Beyerlein A, Verjans E, Wagner N, Von Bernuth H, Lander F, Weil K, Hufnagel M, Spiekerkoetter U, Chao CM, **Naehrlich L**, Muntau AC, Schulze-Sturm U, Hansen G, Wetzke M, Jung AM, Niehues T, Fricke-Otto S, Von Both U, Huebner J, Behrends U, Liese JG, Schwerk C, Drosten C, Von Kries R, Schroten H.. Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021. *Nat Commun*. 2022 Jun 6;13(1):3128. Doi: 10.1038/s41467-022-30482-6.

Graeber SY, Renz DM, Stahl M, Pallenberg ST, Sommerburg O, **Naehrlich L**, Berges J, Dohna M, Ringshausen FC, Doellinger F, Vitzthum C, Röhmel J, Allomba C, Hämmerling S, Barth S, Rückes-Nilges C, Wielpütz MO, Hansen G, Vogel-Claussen J, Tümmler B, Mall MA, Dittrich AM. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two *F508del* Alleles. *Am J Respir Crit Care Med*. 2022 May 10. Doi: 10.1164/rccm.202201-0219OC.

Graeber SY, Vitzthum C, Pallenberg ST, **Naehrlich L**, Stahl M, Rohrbach A, Drescher M, Minso R, Ringshausen FC, Rueckes-Nilges C, Klajda J, Berges J, Yu Y, Scheuermann H, Hirtz S, Sommerburg O, Dittrich AM, Tümmler B, Mall MA. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two *F508del* Alleles. *Am J Respir Crit Care Med*. 2022 Mar 1;205(5):540-549. Doi: 10.1164/rccm.202110-2249OC.

McKone, E, Ariti, C, Jackson, A, Zolin, A, Carr, SB, Orenti, A, Van Rens, J, Lemonnier, L, Macek, M, Keogh RH, **Naehrlich L**, European Cystic Fibrosis Society Patient Registry. Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study. *Eur Respir J* 2021 Oct 1;58(3):2002288. Doi: 10.1183/13993003.02288-2020

Naehrlich L, Orenti A, Dunlevy F, Kasmi I, Harutyunyan S, Pflieger A, Keegan S, Daneau G, Petrova G, Tješić-Drinković D, Yiallourous P, Bilkova A, Olesen HV, Burgel P-R, Parulava T, Diamantea F, Párniczky A, McKone EF, Mei-Zahav M, Salvatore M, Colombo C, Aleksejeva E, Malakauskas K, Schlessner M, Fustik S, Turcu O, Zomer-van Ommen D, Wathne AS, Woźniacki L, Pereira L, Pop L, Kashirskaya N, Rodić M, Kayserova H, Krivecs U, Mondejar-Lopez P, de Monestrol I, Dogru D, Makukh H, Cosgriff R, van Koningsbruggen-Rietschel S, Jung A, European Cystic Fibrosis COVID project group. *Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020*. *J Cyst Fibros* 2021 Jul;20(4):566-577. Doi: 10.1016/j.jcf.2021.03.017

Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Régis P-R Burgel, Tullis E, Castañón C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, **Naehrlich L**, Nasr SZ, Oates GR, O'Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. The future of cystic fibrosis care: a global perspective. *Lancet Resp Med* 2020 Jan;8(1):65-124. Doi: 10.1016/S2213-2600(19)30337-6

Graeber SY*, Dopfer C*, **Naehrlich L***, Gyulumyan L, Scheuermann H, Hirtz S, Wege S, Mairbäurl H, Dorda M, Hyde R, Bagheri-Hanson A, Rueckes-Nilges C, Fischer S, Mall MA, Tümmler B. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. *Am J Respir Crit Care Med* 2018 Jun 1;197(11):1433-1442. Doi: 10.1164/rccm.201710-1983OC. * equal contributors

Dupuis A, Keenan K, Ooi CY, Dorfman R, Sontag MK, **Naehrlich L**, Castellani C, Strug LJ, Rommens JM, Gonska T. Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. *Genet Med* 2016 Apr;18(4):333-340. Doi: 10.1038/gim.2015.79

Breil C, Simon A, Krawinkel MB, **Naehrlich L**. Individualized vitamin A supplementation for patients with cystic fibrosis. *Clin Nutr* 2013;32(5):805-810. Doi: 10.1016/j.clnu.2013.01.009

Mainz JG, **Naehrlich L**, Schien M, Käding M, Schiller I, Mayr S, Schneider G, Wiedemann B, Wiehlmann L, Cramer N, Pfister W, Kahl BC, Beck JF, Tümmler B. Concordant genotype of upper and lower airways *P aeruginosa* and *S aureus* isolates in cystic fibrosis. *Thorax* 2009Jun;64(6): 535-40. Doi: 10.1136/thx.2008.104711